NewsView printer-friendly version
Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in March
- Management participation in a fireside chat at the 38th
Cowen & Company Healthcare Conferenceon Monday, March 12th at 2:50 p.m. ETtaking place in Boston, MA.
- Management participation in a fireside chat is scheduled at Barclays Global Healthcare Conference on
Wednesday, March 14th at 11:15 a.m. ETtaking place in Miami, FL.
The audio portion of the presentations will be available on the investors page of the
Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-1420 (adalimumab biosimilar) and CHS-0214 (etanercept biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology including CHS-3351 (ranibizumab biosimilar) and CHS-2020 (aflibercept biosimilar), and CHS-131, a small molecule for multiple sclerosis. For additional information, please visit www.coherus.com.
Senior Vice President, Investor Relations
+1 (650) 649-3527